Search
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalFDA approved on July 26, 2012.
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Talarozole
go.drugbank.com/drugs/DB13083InvestigationalTalarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigational[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]
Simethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnFood and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from
Cephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Carboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigational[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]